Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 198

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 198
---
 (as a percentage of base salary) Dr. Anzalone (1) 100% 100% Mr. Myszkowski 45% 45% Mr. O’Brien 45% 45% Dr. Hamilton 45% 45% Dr. San Martin 45% 45% Ms. Oliver 40% 40% (1) Dr. Anzalone' annual cash incentive compensation opportunity is capped at 150% of his base salary. Performance Objectives In determining the amount of the annual cash incentive award for each of our executive officers, including each of our NEOs, the Compensation Committee evaluated the corporate performance objectives that had been established at the beginning of the calendar year (as set forth below) as well as other corporate and individual achievements and performance throughout the year. These performance objectives addressed milestones for our lead products, research and development milestones for our drug pipeline and business development objectives. In December 2024, the Compensation Committee determined our performance against our primary business objectives set for calendar 2024, as described below. Goal Achievement Highlights Corporate/ Business Development - Weight: 40% Meet certain goals related to business development, capitalization, long-term financial planning, preparation for commercialization, and utilization of recent capital improvements Met Substantial business development transaction leading to significant recapitalization. Manufacturing supply commitments, utilizing our Verona manufacturing facility, for commercial product. Fully deployed a medical affairs field force and other commercially oriented operations. Clinical Development and Regulatory Affairs - Weight: 40% Meet certain goals relating to Phase 3 studies in our clinical Cardiometabolic programs. Met Launched three Phase 3 studies for plozasiran. Established an Early Access Program for plozasiran in patients with FCS. Submitted a New Drug Application with the U.S. Food and Drug Administration Discovery and Early Development - Weight: 20% Meet certain goals with regard to progress on our pre- clinical and early clinical programs Met. Achieved clinical milestone timelines for seven Phase 1 clinical assets Filed three new clinical trial applications Nominated six new drug candidates Annual Incentive Award Payments The actual annual cash incentive award payments earned by our incumbent NEOs totaled 127% of the respective target award opportunities. Except for the annual incentive award for our CEO, these awards were recommended by our CEO and approved by the Compensation Committee based on the overall achievement of our goals, their contributions to the goals and the overall performance of each executive officer during the year. The following table sets forth the target annual cash incentive award opportunities,